QURE vs. OVID, CDT, ALDX, ACRV, IMMP, FHTX, ACIU, GTHX, TSVT, and GBIO
Should you be buying uniQure stock or one of its competitors? The main competitors of uniQure include Ovid Therapeutics (OVID), Conduit Pharmaceuticals (CDT), Aldeyra Therapeutics (ALDX), Acrivon Therapeutics (ACRV), Immutep (IMMP), Foghorn Therapeutics (FHTX), AC Immune (ACIU), G1 Therapeutics (GTHX), 2seventy bio (TSVT), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
uniQure (NASDAQ:QURE) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.
uniQure currently has a consensus target price of $32.00, indicating a potential upside of 606.40%. Ovid Therapeutics has a consensus target price of $9.00, indicating a potential upside of 190.32%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Ovid Therapeutics.
Ovid Therapeutics has lower revenue, but higher earnings than uniQure. Ovid Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.
78.8% of uniQure shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 4.1% of uniQure shares are owned by insiders. Comparatively, 12.6% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
uniQure has a net margin of -1,947.09% compared to Ovid Therapeutics' net margin of -13,351.53%. Ovid Therapeutics' return on equity of -49.76% beat uniQure's return on equity.
In the previous week, Ovid Therapeutics' average media sentiment score of 0.86 beat uniQure's score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media.
uniQure has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
uniQure received 294 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. Likewise, 70.75% of users gave uniQure an outperform vote while only 70.52% of users gave Ovid Therapeutics an outperform vote.
Summary
uniQure beats Ovid Therapeutics on 10 of the 17 factors compared between the two stocks.
Get uniQure News Delivered to You Automatically
Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
